Paolo has made over 27 trades of the West Pharmaceutical Services stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 1,172,497 units of WST stock worth $5,733,510 on 18 December 2019.
The largest trade he's ever made was exercising 1,172,497 units of West Pharmaceutical Services stock on 18 December 2019 worth over $5,733,510. On average, Paolo trades about 29,932 units every 59 days since 2008. As of 18 December 2019 he still owns at least 1,881,884 units of West Pharmaceutical Services stock.
You can see the complete history of Mr. Pucci stock trades at the bottom of the page.
Paolo Pucci serves as Independent Director of the Company. Mr. Pucci is the recently retired CEO and a former member of the Board of Directors of ArQule, Inc.—a biopharmaceutical company engaged in the research and development of targeted therapeutics. Merck & Co. completed its acquisition of ArQule in January 2020, resulting in Mr. Pucci's retirement. Before joining ArQule in 2008, Mr. Pucci worked at Bayer A.G., where he served in several leadership capacities including Senior Vice President of the Global Specialty Medicine Business Unit and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly and Company, culminating with his appointment as Managing Director, Eli Lilly Sweden AB.
As the Independent Director of West Pharmaceutical Services, the total compensation of Paolo Pucci at West Pharmaceutical Services is $294,072. There are 17 executives at West Pharmaceutical Services getting paid more, with Eric Green having the highest compensation of $6,533,690.
Paolo Pucci is 59, he's been the Independent Director of West Pharmaceutical Services since 2016. There are 8 older and 17 younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services, Inc. is Patrick Zenner, 73, who is the Independent Chairman of the Board.
Paolo's mailing address filed with the SEC is C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, P7, 3584 CT.
Over the last 19 years, insiders at West Pharmaceutical Services have traded over $32,829,857 worth of West Pharmaceutical Services stock and bought 19,924 units worth $1,139,950 . The most active insiders traders include Robert F Friel, Paolo Pucci és Douglas A Michels. On average, West Pharmaceutical Services executives and independent directors trade stock every 40 days with the average trade being worth of $4,786,805. The most recent stock trade was executed by Charles Witherspoon on 19 August 2024, trading 1,029 units of WST stock currently worth $308,700.
west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.
West Pharmaceutical Services executives and other stock owners filed with the SEC include: